Parkinson's disease biomarkers: Perspective from the NINDS Parkinson's Disease Biomarkers Program

Katrina Gwinn, Karen K. David, Christine Swanson-Fischer, Roger Albin, Coryse St Hillaire-Clarke, Beth Anne Sieber, Codrin Lungu, F. Dubois Bowman, Roy N. Alcalay, Debra Babcock, Ted M. Dawson, Richard B. Dewey, Tatiana Foroud, Dwight German, Xuemei Huang, Vlad Petyuk, Judith A. Potashkin, Rachel Saunders-Pullman, Margaret Sutherland, David R. WaltAndrew B. West, Jing Zhang, Alice Chen-Plotkin, Clemens R. Scherzer, David E. Vaillancourt, Liana S. Rosenthal

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's Disease Biomarker Program (PDBP) and other mechanisms, no single PD marker or set of markers are ready for clinical use. Here we discuss the current state of biomarker discovery for platforms relevant to PDBP. We discuss the role of the PDBP in PD biomarker identification and present guidelines to facilitate their development. These guidelines include: harmonizing procedures for biofluid acquisition and clinical assessments, replication of the most promising biomarkers, support and encouragement of publications that report negative findings, longitudinal follow-up of current cohorts including the PDBP, testing of wearable technologies to capture readouts between study visits and development of recently diagnosed (de novo) cohorts to foster identification of the earliest markers of disease onset.

Original languageEnglish (US)
Pages (from-to)451-473
Number of pages23
JournalBiomarkers in Medicine
Volume11
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

National Institute of Neurological Disorders and Stroke
Biomarkers
Parkinson Disease
Guidelines
Publications
Clinical Trials
Technology

All Science Journal Classification (ASJC) codes

  • Drug Discovery
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Gwinn, K., David, K. K., Swanson-Fischer, C., Albin, R., Hillaire-Clarke, C. S., Sieber, B. A., ... Rosenthal, L. S. (2017). Parkinson's disease biomarkers: Perspective from the NINDS Parkinson's Disease Biomarkers Program. Biomarkers in Medicine, 11(6), 451-473. https://doi.org/10.2217/bmm-2016-0370
Gwinn, Katrina ; David, Karen K. ; Swanson-Fischer, Christine ; Albin, Roger ; Hillaire-Clarke, Coryse St ; Sieber, Beth Anne ; Lungu, Codrin ; Bowman, F. Dubois ; Alcalay, Roy N. ; Babcock, Debra ; Dawson, Ted M. ; Dewey, Richard B. ; Foroud, Tatiana ; German, Dwight ; Huang, Xuemei ; Petyuk, Vlad ; Potashkin, Judith A. ; Saunders-Pullman, Rachel ; Sutherland, Margaret ; Walt, David R. ; West, Andrew B. ; Zhang, Jing ; Chen-Plotkin, Alice ; Scherzer, Clemens R. ; Vaillancourt, David E. ; Rosenthal, Liana S. / Parkinson's disease biomarkers : Perspective from the NINDS Parkinson's Disease Biomarkers Program. In: Biomarkers in Medicine. 2017 ; Vol. 11, No. 6. pp. 451-473.
@article{3291c8def2114f568aa665bb8b70aa74,
title = "Parkinson's disease biomarkers: Perspective from the NINDS Parkinson's Disease Biomarkers Program",
abstract = "Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's Disease Biomarker Program (PDBP) and other mechanisms, no single PD marker or set of markers are ready for clinical use. Here we discuss the current state of biomarker discovery for platforms relevant to PDBP. We discuss the role of the PDBP in PD biomarker identification and present guidelines to facilitate their development. These guidelines include: harmonizing procedures for biofluid acquisition and clinical assessments, replication of the most promising biomarkers, support and encouragement of publications that report negative findings, longitudinal follow-up of current cohorts including the PDBP, testing of wearable technologies to capture readouts between study visits and development of recently diagnosed (de novo) cohorts to foster identification of the earliest markers of disease onset.",
author = "Katrina Gwinn and David, {Karen K.} and Christine Swanson-Fischer and Roger Albin and Hillaire-Clarke, {Coryse St} and Sieber, {Beth Anne} and Codrin Lungu and Bowman, {F. Dubois} and Alcalay, {Roy N.} and Debra Babcock and Dawson, {Ted M.} and Dewey, {Richard B.} and Tatiana Foroud and Dwight German and Xuemei Huang and Vlad Petyuk and Potashkin, {Judith A.} and Rachel Saunders-Pullman and Margaret Sutherland and Walt, {David R.} and West, {Andrew B.} and Jing Zhang and Alice Chen-Plotkin and Scherzer, {Clemens R.} and Vaillancourt, {David E.} and Rosenthal, {Liana S.}",
year = "2017",
month = "6",
day = "1",
doi = "10.2217/bmm-2016-0370",
language = "English (US)",
volume = "11",
pages = "451--473",
journal = "Biomarkers in Medicine",
issn = "1752-0363",
publisher = "Future Medicine Ltd.",
number = "6",

}

Gwinn, K, David, KK, Swanson-Fischer, C, Albin, R, Hillaire-Clarke, CS, Sieber, BA, Lungu, C, Bowman, FD, Alcalay, RN, Babcock, D, Dawson, TM, Dewey, RB, Foroud, T, German, D, Huang, X, Petyuk, V, Potashkin, JA, Saunders-Pullman, R, Sutherland, M, Walt, DR, West, AB, Zhang, J, Chen-Plotkin, A, Scherzer, CR, Vaillancourt, DE & Rosenthal, LS 2017, 'Parkinson's disease biomarkers: Perspective from the NINDS Parkinson's Disease Biomarkers Program', Biomarkers in Medicine, vol. 11, no. 6, pp. 451-473. https://doi.org/10.2217/bmm-2016-0370

Parkinson's disease biomarkers : Perspective from the NINDS Parkinson's Disease Biomarkers Program. / Gwinn, Katrina; David, Karen K.; Swanson-Fischer, Christine; Albin, Roger; Hillaire-Clarke, Coryse St; Sieber, Beth Anne; Lungu, Codrin; Bowman, F. Dubois; Alcalay, Roy N.; Babcock, Debra; Dawson, Ted M.; Dewey, Richard B.; Foroud, Tatiana; German, Dwight; Huang, Xuemei; Petyuk, Vlad; Potashkin, Judith A.; Saunders-Pullman, Rachel; Sutherland, Margaret; Walt, David R.; West, Andrew B.; Zhang, Jing; Chen-Plotkin, Alice; Scherzer, Clemens R.; Vaillancourt, David E.; Rosenthal, Liana S.

In: Biomarkers in Medicine, Vol. 11, No. 6, 01.06.2017, p. 451-473.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Parkinson's disease biomarkers

T2 - Perspective from the NINDS Parkinson's Disease Biomarkers Program

AU - Gwinn, Katrina

AU - David, Karen K.

AU - Swanson-Fischer, Christine

AU - Albin, Roger

AU - Hillaire-Clarke, Coryse St

AU - Sieber, Beth Anne

AU - Lungu, Codrin

AU - Bowman, F. Dubois

AU - Alcalay, Roy N.

AU - Babcock, Debra

AU - Dawson, Ted M.

AU - Dewey, Richard B.

AU - Foroud, Tatiana

AU - German, Dwight

AU - Huang, Xuemei

AU - Petyuk, Vlad

AU - Potashkin, Judith A.

AU - Saunders-Pullman, Rachel

AU - Sutherland, Margaret

AU - Walt, David R.

AU - West, Andrew B.

AU - Zhang, Jing

AU - Chen-Plotkin, Alice

AU - Scherzer, Clemens R.

AU - Vaillancourt, David E.

AU - Rosenthal, Liana S.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's Disease Biomarker Program (PDBP) and other mechanisms, no single PD marker or set of markers are ready for clinical use. Here we discuss the current state of biomarker discovery for platforms relevant to PDBP. We discuss the role of the PDBP in PD biomarker identification and present guidelines to facilitate their development. These guidelines include: harmonizing procedures for biofluid acquisition and clinical assessments, replication of the most promising biomarkers, support and encouragement of publications that report negative findings, longitudinal follow-up of current cohorts including the PDBP, testing of wearable technologies to capture readouts between study visits and development of recently diagnosed (de novo) cohorts to foster identification of the earliest markers of disease onset.

AB - Biomarkers for Parkinson's disease (PD) diagnosis, prognostication and clinical trial cohort selection are an urgent need. While many promising markers have been discovered through the National Institute of Neurological Disorders and Stroke Parkinson's Disease Biomarker Program (PDBP) and other mechanisms, no single PD marker or set of markers are ready for clinical use. Here we discuss the current state of biomarker discovery for platforms relevant to PDBP. We discuss the role of the PDBP in PD biomarker identification and present guidelines to facilitate their development. These guidelines include: harmonizing procedures for biofluid acquisition and clinical assessments, replication of the most promising biomarkers, support and encouragement of publications that report negative findings, longitudinal follow-up of current cohorts including the PDBP, testing of wearable technologies to capture readouts between study visits and development of recently diagnosed (de novo) cohorts to foster identification of the earliest markers of disease onset.

UR - http://www.scopus.com/inward/record.url?scp=85021672747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021672747&partnerID=8YFLogxK

U2 - 10.2217/bmm-2016-0370

DO - 10.2217/bmm-2016-0370

M3 - Review article

C2 - 28644039

AN - SCOPUS:85021672747

VL - 11

SP - 451

EP - 473

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

SN - 1752-0363

IS - 6

ER -

Gwinn K, David KK, Swanson-Fischer C, Albin R, Hillaire-Clarke CS, Sieber BA et al. Parkinson's disease biomarkers: Perspective from the NINDS Parkinson's Disease Biomarkers Program. Biomarkers in Medicine. 2017 Jun 1;11(6):451-473. https://doi.org/10.2217/bmm-2016-0370